A comprehensive meta-analysis of 11 trials involving 85,373 participants demonstrated that GLP-1 RAs reduced composite kidney outcomes by 18% (HR 0.82, 95% CI 0.73–0.93), kidney failure by 16% (HR 0.84, 0.72–0.99), MACEs by 13% (HR 0.87, 0.81–0.93), and all-cause death by 12% (HR 0.88, 0.83–0.93) in participants with type 2 diabetes [94,95]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.